Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer
Sponsor: Shandong Suncadia Medicine Co., Ltd.
Summary
This study is a multicenter, open-label, randomized controlled Phase 3 clinical trial. It is planned to enroll 240 female patients with locally advanced or metastatic breast cancer followed by disease progression after previous endocrine therapy.
Official title: A Multicenter, Open-label, Randomized Controlled Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer With Disease Progression After Previous Endocrine Therapy
Key Details
Gender
FEMALE
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
240
Start Date
2025-07-23
Completion Date
2027-12
Last Updated
2026-01-26
Healthy Volunteers
No
Interventions
HRS-8080 Tablet
HRS-8080 tablet orally administered.
Fulvestrant injection
Fulvestrant injection.
Exemestane tablets
Exemestane tablets orally administered.
Everolimus Tablets
Everolimus tablets orally administered.
Anastrozole Tablets
Anastrozole tablets orally administered.
Letrozole Tablets
Letrozole tablets orally administered.
Locations (2)
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
Hunan Cancer Hospital
Changsha, Hunan, China